[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,150,112
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.31
  • Price/Sales 5.38
  • Price/Cash Flow 12.18
  • Price/Book 6.76

Options Overview Details

View History
  • Implied Volatility 28.91% (-0.64%)
  • Historical Volatility 23.58%
  • IV Percentile 41%
  • IV Rank 39.64%
  • IV High 40.29% on 10/13/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 1) 1.70 (1.32%)
  • Put/Call Vol Ratio 1.63
  • Today's Volume 1,890
  • Volume Avg (30-Day) 8,599
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 163,760
  • Open Int (30-Day) 164,502
  • Expected Range 127.14 to 130.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-5.31
  • Number of Estimates 8
  • High Estimate $2.05
  • Low Estimate $-7.50
  • Prior Year $2.01
  • Growth Rate Est. (year over year) -364.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.07 +1.20%
on 06/02/26
137.50 -6.47%
on 05/12/26
-4.09 (-3.08%)
since 05/04/26
3-Month
127.07 +1.20%
on 06/02/26
149.38 -13.91%
on 03/10/26
-19.62 (-13.24%)
since 03/04/26
52-Week
104.46 +23.11%
on 06/25/25
157.29 -18.24%
on 02/11/26
+19.58 (+17.96%)
since 06/04/25

Most Recent Stories

More News
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

– IDEAL Evaluated Livdelzi in People Living with PBC with Elevated ALP Levels (1-1.67xULN) on or Intolerant to UDCA – – 52-Week Results Demonstrate...

GILD : 129.01 (+0.02%)
How Is Gilead Sciences's Stock Performance Compared to Other Healthcare Stocks

Gilead Sciences has outperformed the healthcare sector, and analysts remain highly optimistic about the stock’s outlook

XLV : 151.92 (+2.96%)
GILD : 129.01 (+0.02%)
AMGN : 344.55 (+1.87%)
Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

XLV : 151.92 (+2.96%)
GILD : 129.01 (+0.02%)
AMGN : 344.55 (+1.87%)
Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)

– ALP Is a Key Marker of Disease Activity in People Living With PBC, With Elevations Above Normal Associated with Increased Risk of Disease Progression – ...

GILD : 129.01 (+0.02%)
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference

Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined several upcoming clinical and regulatory priorities across oncology, inflammation and HIV during a discussion with RBC Capital...

GILD : 129.01 (+0.02%)
FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)

– Chronic HDV is considered the most severe form of viral hepatitis due to rapid disease progression towards liver failure and liver-related death – ...

GILD : 129.01 (+0.02%)
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors

– Recommendation Based on ASCENT-03 Study, Demonstrating Highly Statistically Significant and Clinically Meaningful Progression-Free Survival Versus Chemotherapy in PD-(L)1 Inhibitor Ineligible Patients–...

GILD : 129.01 (+0.02%)
NIH Infectious Disease Chief Steps Down Amid Ebola and Hantavirus Response Concerns

The acting director of the National Institute of Allergy and Infectious Diseases resigned ahead of a Senate hearing Thursday, adding to leadership turnover across U.S. health agencies during ongoing Ebola...

GILD : 129.01 (+0.02%)
MRNA : 51.09 (+4.14%)
PFE : 25.82 (+1.89%)
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology

– ASCO Presentations on Trodelvy ® in First-line Metastatic Triple-Negative Breast Cancer and Anito-cel in Relapsed or Refractory Multiple Myeloma Build Toward Potential Commercial...

GILD : 129.01 (+0.02%)
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio

– Acquisition Builds on Gilead’s Leadership in Oncology with Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform –

GILD : 129.01 (+0.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 132.43
2nd Resistance Point 131.14
1st Resistance Point 130.07
Last Price 129.01
1st Support Level 127.71
2nd Support Level 126.42
3rd Support Level 125.35

See More

52-Week High 157.29
Fibonacci 61.8% 137.11
Fibonacci 50% 130.88
Last Price 129.01
Fibonacci 38.2% 124.64
52-Week Low 104.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.